SI2503338T1 - CD73 kot biomarker za spremljanje razvoja bolezni in ocenjevanje učinkovitosti terapij - Google Patents

CD73 kot biomarker za spremljanje razvoja bolezni in ocenjevanje učinkovitosti terapij

Info

Publication number
SI2503338T1
SI2503338T1 SI200831377T SI200831377T SI2503338T1 SI 2503338 T1 SI2503338 T1 SI 2503338T1 SI 200831377 T SI200831377 T SI 200831377T SI 200831377 T SI200831377 T SI 200831377T SI 2503338 T1 SI2503338 T1 SI 2503338T1
Authority
SI
Slovenia
Prior art keywords
biomarker
therapies
assessing
efficacy
diseases
Prior art date
Application number
SI200831377T
Other languages
English (en)
Slovenian (sl)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of SI2503338T1 publication Critical patent/SI2503338T1/sl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
SI200831377T 2007-10-24 2008-10-15 CD73 kot biomarker za spremljanje razvoja bolezni in ocenjevanje učinkovitosti terapij SI2503338T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20070795A FI20070795A0 (fi) 2007-10-24 2007-10-24 Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
EP12002502.8A EP2503338B1 (en) 2007-10-24 2008-10-15 CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies

Publications (1)

Publication Number Publication Date
SI2503338T1 true SI2503338T1 (sl) 2015-06-30

Family

ID=38656804

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200831377T SI2503338T1 (sl) 2007-10-24 2008-10-15 CD73 kot biomarker za spremljanje razvoja bolezni in ocenjevanje učinkovitosti terapij
SI200830723T SI2201376T1 (sl) 2007-10-24 2008-10-15 Nov biomarker za monitoring razvoja bolezni in določanje učinkovitosti terapij

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200830723T SI2201376T1 (sl) 2007-10-24 2008-10-15 Nov biomarker za monitoring razvoja bolezni in določanje učinkovitosti terapij

Country Status (14)

Country Link
US (1) US20100209942A1 (https=)
EP (2) EP2201376B1 (https=)
JP (2) JP4982610B2 (https=)
KR (2) KR20100059902A (https=)
CA (1) CA2702635A1 (https=)
CY (2) CY1113403T1 (https=)
DK (2) DK2201376T3 (https=)
ES (2) ES2389751T3 (https=)
FI (1) FI20070795A0 (https=)
HR (2) HRP20120743T1 (https=)
PL (2) PL2201376T3 (https=)
PT (2) PT2503338E (https=)
SI (2) SI2503338T1 (https=)
WO (1) WO2009053523A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340916B (es) 2008-01-18 2016-07-29 President And Fellows Of Harvard College * Metodos para detectar señales de identificacion de enfermedad o condiciones en fluidos corporales.
AU2011281012A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting cardiovascular diseases or conditions
TW201209171A (en) 2010-07-23 2012-03-01 Harvard College Methods of detecting diseases or conditions using phagocytic cells
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
EP2596132A4 (en) 2010-07-23 2013-12-18 Harvard College METHOD FOR DETECTING SIGNS FOR ILLNESS OR SUFFERING IN BODY FLUIDS
JP2015522260A (ja) 2012-06-15 2015-08-06 ハリー スティリ， 疾患または状態を検出する方法
MX2014015434A (es) 2012-06-15 2015-07-14 Harry Stylli Metodos para detectar enfermedades o condiciones utilizando celulas enfermas en circulacion.
PL2956772T3 (pl) * 2013-02-14 2018-12-31 Faron Pharmaceuticals Oy Sposób określenia biomarkerów związanych z zespołem ostrej niewydolności oddechowej (ARDS), sposób monitorowania rozwoju i leczenia ARDS u pacjenta
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
GB201706747D0 (en) * 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515965A (ja) * 1995-08-18 2002-05-28 ダブリュー． ランドリ，ドナルド 抗体触媒反応の調節による有機化合物の検出
EP0862652A1 (en) 1995-10-13 1998-09-09 IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
HUP0002003A3 (en) 2000-05-24 2003-01-28 Pronuk Biotechnologia Kft Process and reagent-kit for determining of 5'-nucleotidase activity
CA2439961A1 (en) * 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
FI20030467A0 (fi) * 2003-03-28 2003-03-28 Sirpa Jalkanen Menetelmä tulehdustilojen hoitamiseen
US7534423B2 (en) 2003-03-28 2009-05-19 Faron Pharmaceuticals Oy Method for inducing an elevated level of adenosine in an individual
CA2528152A1 (en) * 2003-06-03 2005-01-06 The Regents Of The University Of California Compositions and methods for treatment of disease with acetylated disaccharides
JP2009505658A (ja) * 2005-08-24 2009-02-12 ブリストル−マイヤーズ スクイブ カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
EP2021350B1 (en) * 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Phosphorylated a2a receptor agonists
EP2041574B1 (en) * 2006-07-14 2016-11-16 The Regents of The University of California Cancer biomarkers and methods of use threof

Also Published As

Publication number Publication date
PT2503338E (pt) 2015-03-05
WO2009053523A1 (en) 2009-04-30
CA2702635A1 (en) 2009-04-30
ES2532361T3 (es) 2015-03-26
EP2201376B1 (en) 2012-08-08
EP2503338B1 (en) 2014-12-24
JP5619810B2 (ja) 2014-11-05
PL2201376T3 (pl) 2013-01-31
US20100209942A1 (en) 2010-08-19
HRP20120743T1 (hr) 2012-10-31
EP2201376A1 (en) 2010-06-30
JP2012159514A (ja) 2012-08-23
EP2201376A4 (en) 2011-03-23
FI20070795A0 (fi) 2007-10-24
DK2201376T3 (da) 2012-10-15
JP4982610B2 (ja) 2012-07-25
ES2389751T3 (es) 2012-10-31
CY1116089T1 (el) 2017-02-08
PL2503338T3 (pl) 2015-06-30
EP2503338A2 (en) 2012-09-26
JP2011501176A (ja) 2011-01-06
CY1113403T1 (el) 2016-06-22
KR20160029869A (ko) 2016-03-15
SI2201376T1 (sl) 2012-09-28
KR20100059902A (ko) 2010-06-04
DK2503338T3 (en) 2015-03-09
HRP20150181T1 (hr) 2015-06-19
EP2503338A3 (en) 2013-03-13
PT2201376E (pt) 2012-08-20

Similar Documents

Publication Publication Date Title
SI2503338T1 (sl) CD73 kot biomarker za spremljanje razvoja bolezni in ocenjevanje učinkovitosti terapij
SG176655A1 (en) New biomarkers for assessing kidney diseases
GB0724735D0 (en) Methods and biomarkers for diagnosing and monitoring psychotic disorders
GB0701626D0 (en) Methods and biomarkers for diagnosing and monitoring psychotic disorders
GB0624858D0 (en) Battery Monitoring
IL219210A0 (en) Biomarkers and methods for measuring and monitoring inflammatory disease activity
GB0608829D0 (en) In-situ measurement of physical parameters
GB0717637D0 (en) Future cardiac event biomarkers
GB2450351B (en) Monitoring an Immunoassay
IL206631A0 (en) Biomarkers for the prediction of renal injury
IL217725A0 (en) Means and methods for diagnosing thyroid disorders
EP2260107A4 (en) TESTS FOR THE DIAGNOSIS AND ASSESSMENT OF TREATMENT OPTIONS FOR MORBUS POMPE
TWI351185B (en) Methods for interference measurement and prediction
GB0722068D0 (en) Predictive test
GB0720433D0 (en) Usage monitoring
GB0712407D0 (en) Authorised debugging
GB0704515D0 (en) Diagnosing psychotic disorders
AU2009900444A0 (en) Agents and methods for diagnosing the presence or risk of a condition
GB0606920D0 (en) Biomarker for schizophrenic disorders
PL382585A1 (pl) Sposób realizowania transakcji handlowych
PL381454A1 (pl) Sposób diagnozowania stanu technicznego obiektów mostowych
AU2008902580A0 (en) Agents and methods for diagnosing the presence or risk of a condition
GB0720545D0 (en) Diagnosing physchotic disorders
GB0622351D0 (en) Non-invasive monitoring
PL381670A1 (pl) Sposób monitorowania elementów konstrukcji